Orexo publishes prospectus and applies for admission to trading of social bonds on Nasdaq Stockholm

For further information please contact:Nikolaj Sørensen, President and CEOFredrik Järrsten, EVP and CFOLena Wange, IR & Communications DirectorTel: +46 (0)18 780 88 00E-mail: ir@orexo.com For further information please contact:Nikolaj Sørensen, President and CEO Fredrik Järrsten, EVP and CFOLena Wange, IR & Communications Director Tel: +46 (0)18 780 88 00 E-mail:ir@orexo.com About OrexoOrexo is a Swedish pharmaceutical company with over 25 years of experience developing...

Sweden, 10/05/2024 (informazione.it - comunicati stampa - salute e benessere)

Nikolaj Sørensen, President and CEO
Fredrik Järrsten, EVP and CFO
Lena Wange , IR & Communications Director
Tel: +46 (0)18 780 88 00
E-mail: ir@orexo.com

Orexo is a Swedish pharmaceutical company with over 25 years of experience developing improved pharmaceuticals based on proprietary formulation technologies that meet large medical needs. On the US market, Orexo provides innovative treatment solutions for patients suffering from opioid use disorder and adjacent diseases. Products targeting other therapeutic areas are developed and commercialized worldwide with leading partners. Total net sales in 2023 amounted to SEK 639 million , and the number of employees to 116. Orexo is listed on Nasdaq Stockholm's main list and is available as an ADR on OTCQX (ORXOY) in the US.

For more information about Orexo please visit www.orexo.com . You can also follow Orexo on X, LinkedIn, and YouTube.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/orexo/r/orexo-publishes-prospectus-and-applies-for-admission-to-trading-of-social-bonds-on-nasdaq-stockholm,c3976889

The following files are available for download:

 

View original content: https://www.prnewswire.co.uk/news-releases/orexo-publishes-prospectus-and-applies-for-admission-to-trading-of-social-bonds-on-nasdaq-stockholm-302142316.html